Arbutus Biopharma
ABUS
53 hedge funds and large institutions have $118M invested in Arbutus Biopharma in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 10 closing their positions.
33% more capital invested
Capital invested by funds: $88.8M → $118M (+$29.2M)
0.03% more ownership
Funds ownership: 65.99% → 66.02% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 55 → 53 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
38% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 21
39% less call options, than puts
Call options by funds: $106K | Put options by funds: $175K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$4.01M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$716K |
| 3 |
Renaissance Technologies
New York
|
+$307K |
| 4 |
Invesco
Atlanta,
Georgia
|
+$274K |
| 5 |
TI
Telemetry Investments
New York
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWG
Alpha Wave Global
New York
|
-$1.5M |
| 2 |
AC
Armistice Capital
New York
|
-$943K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$573K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$401K |
| 5 |
Goldman Sachs
New York
|
-$340K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
US Bancorp
Minneapolis,
Minnesota
| $1K | – | – | – |
|
|
SIM
52
Sonora Investment Management
Tucson,
Arizona
| $65 | – | – | – |
|
|
DCM
53
DAFNA Capital Management
Los Angeles,
California
| – | -$573K | -234,000 | Closed |
|
|
AFM
54
Anson Funds Management
Dallas,
Texas
| – | -$257K | -105,085 | Closed |
|
|
DTL
55
Dynamic Technology Lab
Singapore
| – | -$98K | -40,017 | Closed |
|
|
DCM
56
Dialectic Capital Management
Norwalk,
Connecticut
| – | -$61K | -25,000 | Closed |
|
|
VKH
57
Virtu KCG Holdings
New York
| – | -$58K | -23,700 | Closed |
|
|
SFM
58
Sphera Funds Management
Tel Aviv,
Israel
| – | -$54K | -22,000 | Closed |
|
|
TC
59
TFS Capital
West Chester,
Pennsylvania
| – | -$35K | -14,195 | Closed |
|
60
Squarepoint
New York
| – | -$33K | -13,400 | Closed |
|
|
JG
61
Jefferies Group
New York
| – | -$25K | -10,300 | Closed |
|
62
Walleye Trading
New York
| – | -$17K | -7,000 | Closed |
|
ABUS Hedge Fund Activity: Q1 2017 in Review
53 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2017, worth a combined $118M — up 33% from $88.8M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ABUS and 8 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 13 added.
The largest buyer was RTW Investments, opening a new position worth an estimated $4.01M. The largest seller was Alpha Wave Global, cutting an estimated $1.5M.
- 53 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2017, down from 55 in Q4 2016.
- Funds reported $118M of Arbutus Biopharma stock for Q1 2017, up 33% quarter-over-quarter.
- 8 funds opened new Arbutus Biopharma positions in Q1 2017 and 10 closed out, a net change of -2 holders.
- The largest Arbutus Biopharma buyer in Q1 2017 was RTW Investments, an estimated $4.01M added.
- The largest Arbutus Biopharma seller in Q1 2017 was Alpha Wave Global, an estimated $1.5M sold.
Based on aggregated 13F filings for Q1 2017.